Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Investigation of usability of combination therapy with S-1 plus panitumumab in patients with KRAS wild type unresectable advanced and recurrent colorectal cancer, who had previously received on fluoropyrimidine, oxaliplatin and irinotecan ; phase II study.

ABSTRACT: Interventions: Panitumumab/S-1 combination therapy Panitumumab 6mg/kg, biweekly S-1 80mg/m2/day, po from day 1 to 28 of each 42 days cycle Primary outcome(s): Progression free survival (PFS) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2622693 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Multicenter Phase II Study of Panitumumab and Irinotecan with or without Fluoropyrimidines in patients with KRAS Wild-type Metastatic Colorectal Cancer (PACIFIC)

Project description:Interventions: Irinotecan 150 mg/m2/biweekly div l-LV 200mg/m2/biweekly div 5-FU/bolus 400mg/m2/biweekly div (bolus) 5-FU/infusional 2,400mg/m2/biweekly div Panitumumab 6mg/kg/biweekly div or S-1 80mg/m2/day p.o. day 1-7 Irinotecan 150mg/m2 day 1 Panitumumab 6mg/kg/biweekly div Irinotecan 150mg/m2/ biweekly div Panitumumab 6mg/kg/biweekly div Primary outcome(s): Progression-free survival Study Design: Parallel Randomized

| 2623074 | ecrin-mdr-crc

Phase II Study of Panitumumab with Fluorouracil in Patients With KRAS Wild-type Metastatic Colorectal Cancer(PF Study)

Project description:Interventions: l-LV 200mg/m2 day 1 5-FU/bolus 400mg/m2 day1 5-FU/infusional 2,400mg/m2 day1-2 Panitumumab 6mg/kg day 1 Biweekly or Capecitabine 2,000mg/m2/day day1-7 Panitumumab 6mg/kg day1 Biweekly or S-1 80mg/m2/day day1-7 Panitumumab 6mg/kg day1 Biweekly or UFT 300mg/m2/day day1-7 LV 75 mg/m2/day day1-7 Panitumumab 6mg/kg day1 Biweekly Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2622610 | ecrin-mdr-crc

Skin Toxicity Prevention Protocol with Panitumumab treatment for Metastatic Colorectal Cancer

Project description:Interventions: A group Panitumumab is administered intravenously in 6mg/kg by biweekly skin care+antibiotics Clarithromycin is administered orally twice a day B group Panitumumab is administered intravenously in 6mg/kg by biweekly skin care only Primary outcome(s): incidence rates of skin toxicity (>=Grade2) with or without antibiotics during the 6 weeks from the treatment started Study Design: Parallel Randomized

| 2626856 | ecrin-mdr-crc

Phase II study of combination therapy with S-1 plus cetuximab in patients with EGFR positive KRAS wild type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine(KSCC0901).

Project description:Interventions: Cetuximab/S-1 combination therapy Cetuximab weekly administration 400 mg/m2(day1), 250mg/m2/week(except day1) S-1 80-120mg/day, PO from day1 to day 28 of each 42 day cycle. Primary outcome(s): Progression free survival(PFS) Study Design: Single arm Non-randomized

| 2617952 | ecrin-mdr-crc

Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY)

Project description:Interventions: Irinotecan plus S-1 (IRSI) with biweekly cetuximab combination therapy 1)Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD 2)S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks 3)Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2622245 | ecrin-mdr-crc

A multicenter phase II trial of TS-1+oxaliplatin+panitumumab as first-line treatment in patients with kras-wild type unresectable advanced colorectal liver metastasis.

Project description:Interventions: Dosing period: until progression disease Dose: TS-1 80mg/m2 (day1 to day15) Oxaliplatin 130mg/m2 (day1) panitumumab 6mg/kg (day1) every 3 weeks Primary outcome(s): RR: response rate Study Design: Single arm Non-randomized

| 2622655 | ecrin-mdr-crc

The study of feasibility and usefulness of olanzapine for the patients who received oxaliplatin chemotherapy.

Project description:Interventions: Olanzapine; 5mg PO on days 1 to 4 Aprepitant; 125 mg PO on day 1, 80 mg PO on days 2 to 3 5HT3-receptor antagonist; IV administration on day 1 Dexamethasone; 6.6 mg IV on day 1, 4 mg PO on days 2 to 3 Primary outcome(s): The rate of adverse events Study Design: Single arm Non-randomized

| 2647713 | ecrin-mdr-crc

Feasibility study of combination therapy with S-1 plus irinotecan in patients with EGFR positive KRAS mutation type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine, bevacizumab

Project description:Interventions: S-1/irinotecan combination therapy Irinotecan 100 mg/m2(day1,15), S-1 80-120mg/day, PO from day1 to day 14 of each 28 day cycle. Primary outcome(s): Progression free survival(PFS) Study Design: Single arm Non-randomized

| 2625128 | ecrin-mdr-crc

Effect of neonatal right ventricular pressure overload on gene expression and regions of open chromatin during postnatal heart development

Project description:To investigate the effect of pressure overload (PO) during postnatal right ventricular (RV) development, we established the RV PO model by conducting pulmonary artery banding (PAB) surgery on neonatal Sprague-Dawley (SD) rats. We then performed gene expression and chromatin openness profiling analysis using data obtained from RNA-seq and ATAC-seq of RV free walls from PO and sham-operated rats at postnatal day 21 (P21).

2024-05-17 | GSE210180 | GEO

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer

Project description:Interventions: Irinotecan plus S-1 with cetuximab combination therapy Cetuximab 400mg/m2 day1 and then 250mg/m2 day 8,15,22 weekly until PD, or Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD S-1 S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2620325 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data